Chardan Capital reiterated their buy rating on shares of REGENXBIO Inc. (NASDAQ:RGNX) in a research note released on Tuesday. Chardan Capital currently has a $75.00 price objective on the biotechnology company’s stock, up from their previous price objective of $55.00.

RGNX has been the subject of a number of other research reports. Zacks Investment Research downgraded REGENXBIO from a buy rating to a hold rating in a report on Thursday, August 17th. Evercore ISI began coverage on REGENXBIO in a report on Wednesday, August 16th. They issued an outperform rating and a $25.00 price objective for the company. Finally, BidaskClub upgraded REGENXBIO from a hold rating to a buy rating in a report on Saturday, August 12th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $37.00.

REGENXBIO (NASDAQ:RGNX) opened at 25.70 on Tuesday. REGENXBIO has a 52-week low of $12.82 and a 52-week high of $25.85. The firm’s market cap is $793.98 million. The company has a 50 day moving average price of $20.66 and a 200-day moving average price of $19.84.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.34. The business had revenue of $6.56 million during the quarter. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. Equities research analysts anticipate that REGENXBIO will post ($2.87) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/09/chardan-capital-reaffirms-buy-rating-for-regenxbio-inc-rgnx.html.

In other REGENXBIO news, insider Kenneth T. Mills sold 10,500 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $25.00, for a total value of $262,500.00. Following the completion of the transaction, the insider now directly owns 118,530 shares of the company’s stock, valued at $2,963,250. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Stephen Yoo sold 32,658 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $25.00, for a total value of $816,450.00. Following the completion of the transaction, the insider now directly owns 31,803 shares of the company’s stock, valued at $795,075. The disclosure for this sale can be found here. Insiders sold 91,898 shares of company stock valued at $2,141,135 in the last quarter. 17.00% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of RGNX. Teachers Advisors LLC grew its stake in REGENXBIO by 3.4% in the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $629,000 after acquiring an additional 1,102 shares during the period. Nationwide Fund Advisors grew its stake in REGENXBIO by 7.7% in the first quarter. Nationwide Fund Advisors now owns 45,955 shares of the biotechnology company’s stock valued at $887,000 after acquiring an additional 3,280 shares during the period. Acadian Asset Management LLC acquired a new position in REGENXBIO in the first quarter valued at about $272,000. Strs Ohio grew its stake in REGENXBIO by 93.5% in the first quarter. Strs Ohio now owns 32,900 shares of the biotechnology company’s stock valued at $634,000 after acquiring an additional 15,900 shares during the period. Finally, Swiss National Bank grew its stake in REGENXBIO by 30.7% in the first quarter. Swiss National Bank now owns 42,600 shares of the biotechnology company’s stock valued at $822,000 after acquiring an additional 10,000 shares during the period. 73.23% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Receive News & Stock Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related stocks with our FREE daily email newsletter.